Effects of Spironolactone on Matrix Metalloproteinases (MMPs) in Heart Failure - Tabular View

Tracking Information
First Received Date ^ICMJE	April 18, 2008
Last Updated Date	April 18, 2008
Start Date ^ICMJE	January 2004
Primary Completion Date
Current Primary Outcome Measures ^ICMJE (submitted: April 18, 2008)	MMP levels [ Time Frame: 16 weeks ]
Original Primary Outcome Measures ^ICMJE	Same as current
Change History	No Changes Posted
Current Secondary Outcome Measures ^ICMJE
Original Secondary Outcome Measures ^ICMJE

Descriptive Information
Brief Title ^ICMJE	Effects of Spironolactone on Matrix Metalloproteinases (MMPs) in Heart Failure
Official Title ^ICMJE	Effects of Spironolactone on Circulating MMPs in Patients With Chronic Heart Failure
Brief Summary	The purpose of this study is to evaluate the effects of spironolactone on circulating MMP levels and insulin resistance in patients with chronic heart failure.
Detailed Description	Myocardial fibrosis is observed in failing hearts. MMPs are considered markers of fibrosis. Recently, circulating MMPs can be measured and are elevated in patients with chronic heart failure (CHF). It has been reported that spironolactone improves myocardial fibrosis in CHF animal models. Therefore, the purpose of this study is to evaluate the effects of spironolactone on circulating MMP levels in patients with chronic heart failure.
Study Phase	Phase IV
Study Type ^ICMJE	Interventional
Study Design ^ICMJE	Treatment, Randomized, Double Blind (Subject, Investigator), Active Control, Crossover Assignment, Efficacy Study
Condition ^ICMJE	Chronic Stable Heart Failure
Intervention ^ICMJE	Drug: spironolactone + furosemide
Study Arms / Comparison Groups
Publications *
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information
Recruitment Status ^ICMJE	Completed
Enrollment ^ICMJE	16
Completion Date	December 2005
Primary Completion Date
Eligibility Criteria ^ICMJE	Inclusion Criteria: chronic stable heart failure
Gender	Both
Ages
Accepts Healthy Volunteers
Contacts ^ICMJE	Contact information is only displayed when the study is recruiting subjects
Location Countries ^ICMJE

Administrative Information
NCT ID ^ICMJE	NCT00663195
Responsible Party	Kazuhide Ogino, Center for Clinical Residency Program, Tottori University Hospital
Study ID Numbers ^ICMJE	#344
Study Sponsor ^ICMJE	Tottori University Hospital
Collaborators ^ICMJE
Investigators ^ICMJE
Information Provided By	Tottori University Hospital
Verification Date	April 2008
^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP